

CORPORATE NEWS

MeVis Medical Solutions AG
Caroline-Herschel-Straße 1
28359 Bremen
Germany

Phone: +49 421 224 95 0
Fax: +49 421 224 95 999
E-mail: ir@mevis.de

MeVis Q1 2015: Mixed first quarter

Very positive sales by strong US Dollar, declining results

- Sales in the first quarter increased by 21 % to €3.4 m due to the strong US dollar (previous year: €2.8 m)
- Earnings before interest and taxes (EBIT) decreased to €0.5 m (previous year €0.7 m), EBIT margin of 16 %
- Net profit also declined slightly to €0.7 m (previous year €0.8 m)
- Liquidity of €19.0 m as at March 31, 2015 (Dec. 31, 2014: €17.5 m)

Bremen, May 21, 2015 – MeVis Medical Solutions AG [ISIN: DE000A0LBFE4], a leading provider of medical imaging software, today announced its results for the first quarter of 2015.

Sales in the first quarter of 2015 came to €3,408 k, 21 % higher than in the first quarter of 2014 (€2,828 k). Revenues generated from licensing business increased by 17 % to T€1,561, revenues from maintenance business increased by 9 % and accounted with T€1,493 for 44 % of total sales. Sales in the Digital Mammography segment grew by 22 % to €2,721 k (prev. year: €2,227 k) and sales in the Other Diagnostics segment grew by 14 % to €687 k (prev. year: €601 k).

Sales increased year-on-year by 21 %, almost entirely attributable to the US\$ development

Operating expenses increased slightly in the first quarter of 2015. Staff costs increased by only 1 % to €1,837 k (prev. year: €1,812 k). Other operating expenses rose by 34 % to €549 k (prev. year: €411 k) driven by legal and consulting cost.

Staff costs almost at same level, and other operating expenses significantly increased due to transaction

The capitalization of development expenses was ceased in the fourth quarter of 2014 (Q1 2014: €428 k).

Due to increased sales and despite higher costs and the cessation of the capitalization of development expenses, we see a slight increase of the EBITDA (earnings before interest, taxes, depreciation and amortization) by 1 %, from €1,100 k to €1,107 k.

After depreciation and amortization of € 565 k (up 39 % year on year), EBIT (earnings before interest and taxes) declined considerably by 22 % to € 542 k (prev. year: € 694 k) corresponding to an EBIT margin of 16 % (prev. year: 25 %).

EBIT significantly lower than prior year, margin of 16 %

The net financial result improved by € 59 k to € 138 k year on year. Mainly the development of the US\$ exchange rate, the continuous improvement of the MeVis BreastCare, and the interest result have contributed to this. Income tax expenses decreased by € 46 k to € 42 k.

Net profit fell by € 47 k to € 683 k, which is equivalent to earnings per share of € 0,37 (prev. year: 0,40).

Earnings per share of € 0.37

Cash and cash equivalents increased by € 1.453 k to € 18.964 k as of March 31, 2015 compared to the end of 2014.

The Company's financial reports can be downloaded from the following website:

<http://www.mevis.de/en/investor-relations/financial-reports/>

MeVis Medical Solutions AG was founded in 1997 and is one of the world's leading independent developer and provider of medical imaging software with focus on dedicated, disease-oriented clinical applications. MeVis AG has been listed on the Frankfurt Stock Exchange in the Prime Standard segment of the Regulated Market since November 16, 2007.

Over the past few years, there has been an enormous increase in the complexity and volume of medical imaging data derived from diagnostic imaging processes such as digital mammography, computed tomography (CT), magnetic resonance imaging (MRI), and ultrasound (US). MeVis' products analyze and process this data in such a way as to provide medical professionals with crucial information for early detection, diagnosis and intervention in the areas of cancer and lung diseases as well as neurological disorders. The Company develops its software solutions in close consultation with world's leading medical experts and original equipment manufacturers (OEM) in the medical technology sector and primarily markets this software via these partnerships.